Emergent Biosolutions (ER4) AI Stock Analysis

2 Followers

Emergent Biosolutions

(BX Swiss:ER4)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationStrong year-to-date EBITDA and operating cash flow provide internal funding for operations, debt service and selected growth initiatives. This improves resilience during uneven government delivery cycles, although the durability of cash conversion depends on improving underlying earnings quality.

Negative Factors

Declining revenue and delivery dependenceLarge year-over-year revenue declines and expected MCM contraction show that sales remain highly dependent on the timing of government and international deliveries. This creates uneven utilization and makes near-term operating performance less predictable even when contracts remain strategically valuable.

Emergent Biosolutions (ER4) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 310.55M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -1.2
Beta (1Y): -0.18
Revenue Growth: -23.26%
EPS Growth: -432.87%
Country: Switzerland
Employees: 900
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Emergent Biosolutions Business Overview & Revenue Model

Company Description

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and natu...

Emergent Biosolutions Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:29.46%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call was generally positive, emphasizing strong year-to-date cash generation, debt reduction, cost-management actions, international MCM diversification, continued naloxone market leadership and progress on growth programs. These positives were tempered by a substantial year-over-year third-quarter revenue decline, negative quarterly adjusted EBITDA, competitive pricing and volume pressure in naloxone, an expected full-year MCM revenue decline and uncertainty around the timing of government and international deliveries.

Positive Updates

Third-Quarter Revenue Met Guidance

Third-quarter revenue was $110 million, within the company's guidance range, bringing year-to-date revenue to $500 million.

Negative Updates

Third-Quarter Revenue Declined Significantly Year-over-Year

Third-quarter revenue was $110 million versus $231 million in the third quarter of 2025. The comparison was primarily influenced by the timing of MCM deliveries, including accelerated deliveries in the second quarter of 2026.

Company Guidance

Emergent now expects full year 2026 total revenues of $600 million to $645 million; MCM revenues are expected to decline versus the prior year based on the timing of remaining international MCM deliveries and U.S. government procurement, while Commercial revenue is currently tracking towards the lower end of the 20% to 25% range of revenue reduction versus 2025. The company expects adjusted gross margin of 45% to 47%, a 300 basis point improvement versus its August guidance, and adjusted EBITDA of $110 million to $140 million, with the upper end of the range consistent with the midpoint of its prior guidance. Restructuring actions are expected to generate approximately $40 million of annualized savings, with the initial impact becoming evident in the fourth quarter of 2026; some orders internationally and with the U.S. government may materialize this year or in the early part of next year.

Emergent Biosolutions Risk Analysis

Emergent Biosolutions disclosed 59 risk factors in its most recent earnings report. Emergent Biosolutions reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We cannot guarantee that our 2025 Share Repurchase Program will be utilized in full, or at all, or that our 2025 Share Repurchase Program will enhance long-term stockholder value.Q4, 2025

2.Divestitures and sales of assets could negatively impact our business, and retained liabilities from businesses or assets that we have sold could adversely affect our financial results.Q4, 2025

3.Changes to tax legislation may adversely affect our business.Q4, 2025

Emergent Biosolutions Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:ER4 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	77Outperform	$1.24B	12.71	12.59%	―	3.11%	-4.26%
TLPH	58Neutral	$54.50M	-3.29	-87.28%	―	-96.30%	35.57%
SIGA	54Neutral	$224.91M	490.62	0.42%	―	-69.60%	-99.10%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVO	50Neutral	$614.69M	-3.10	-25.63%	―	0.31%	-19.37%
CPIX	49Neutral	$79.41M	1.33	202.58%	22.65%	-39.11%	-241.27%

* Healthcare Sector Average

Performance Comparison

CH:ER4 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:ER4	Emergent Biosolutions	5.04	1.15	29.46%
TLPH	Talphera, Inc.	1.05	0.00	0.00%
SIGA	Siga Technologies	3.14	-2.24	-41.61%
AMPH	Amphastar Pharmaceuticals Inc	28.60	2.23	8.46%
EVO	Evotec Ag (Adr)	1.69	-1.48	-46.69%
CPIX	Cumberland Pharmaceuticals Inc.	6.12	4.50	277.78%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Emergent Biosolutions AI Stock Analysis